BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard therapy is available. This study will enroll adult patients with metastatic colorectal cancer who progressed after at least two lines of therapy.
Metastatic Colorectal Cancer
DRUG: Dose level 1 ONC201 625mg|DRUG: Dose level 2 ONC201 500mg|DRUG: Dose level 3 ONC201 375mg
Maximum Tolerated Dose of ONC201 With Nivolumab for Phase II, Cycle 1 (each cycle is approximately 4 weeks) through pre-dosing cycle 2, approximately 1 month|Progression Free Survival, Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions., From start of protocol therapy until death or progression, a maximum of 6 months from end of therapy.
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard therapy is available. This study will enroll adult patients with metastatic colorectal cancer who progressed after at least two lines of therapy.